Literature DB >> 25735428

Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis.

A Casutt1, H Bouchaab, C Beigelman-Aubry, J Bourhis, A Lovis, O Matzinger.   

Abstract

OBJECTIVE: This study investigated the effectiveness of stereotactic body radiotherapy with helical TomoTherapy (T-SBRT) for treating medically inoperable primary and second-primary early stage non-small-cell lung neoplasm (SPLN) and evaluated whether the movement of organizing pneumonia (OP) within the irradiation field (IF) can be detected via analysis of radiological changes.
METHODS: Patients (n = 16) treated for 1 year (2011-12) at our hospital by T-SBRT at a total dose of 60 Gy in five fractions were examined retrospectively. Outcome and toxicity were recorded and were separately described for SPLN. CT scans were reviewed by a single radiologist.
RESULTS: Of the 16 patients, 5 (31.3%) had primary lung malignancies, 10 (62.5%) had SPLN, and 1 case (6.3%) had isolated mediastinal metastasis of lung neoplasm. Pathological evidence was obtained for 72.2% of all lesions. The median radiological follow-up was 11 months (10.5 months for SPLN). For all cases, the 6- and 12-month survival rates were 100% and 77.7% (100% and 71.4%, respectively, for SPLN), and the 6- and 12-month locoregional control rates were 100% in all cases. 2 (12.5%) of 16 patients developed grade 3 late transient radiation pneumonitis following steroid therapy and 1 (6.3%) presented asymptomatic infiltrates comparable to OP opacities.
CONCLUSION: T-SBRT seems to be safe and effective. ADVANCES IN KNOWLEDGE: Mild OP is likely associated with radiation-induced anomalies in the IF, identification of migrating opacities can help discern relapse of radiation-induced opacities.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25735428      PMCID: PMC4628475          DOI: 10.1259/bjr.20140687

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  17 in total

1.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Authors:  Sashendra Senthi; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Lancet Oncol       Date:  2012-06-22       Impact factor: 41.316

2.  Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.

Authors:  Yukinori Matsuo; Keiko Shibuya; Mitsuhiro Nakamura; Masaru Narabayashi; Katsuyuki Sakanaka; Nami Ueki; Ken Miyagi; Yoshiki Norihisa; Takashi Mizowaki; Yasushi Nagata; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-19       Impact factor: 7.038

3.  Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.

Authors:  Frank J Lagerwaard; Naomi E Verstegen; Cornelis J A Haasbeek; Ben J Slotman; Marinus A Paul; Egbert F Smit; Suresh Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-19       Impact factor: 7.038

4.  Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.

Authors:  Mojgan Taremi; Andrew Hope; Max Dahele; Shannon Pearson; Sharon Fung; Thomas Purdie; Anthony Brade; John Cho; Alexander Sun; Jean-Pierre Bissonnette; Andrea Bezjak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-04       Impact factor: 7.038

5.  Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT.

Authors:  Toshiaki Takeda; Atsuya Takeda; Etsuo Kunieda; Akitoshi Ishizaka; Kazuhiko Takemasa; Kyoko Shimada; Seika Yamamoto; Naoyuki Shigematsu; Osamu Kawaguchi; Jun-Ichi Fukada; Toshio Ohashi; Sachio Kuribayashi; Atsushi Kubo
Journal:  AJR Am J Roentgenol       Date:  2004-05       Impact factor: 3.959

6.  Second primary lung cancer.

Authors:  T Antakli; R F Schaefer; J E Rutherford; R C Read
Journal:  Ann Thorac Surg       Date:  1995-04       Impact factor: 4.330

7.  Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy.

Authors:  Cornelis J A Haasbeek; Frank J Lagerwaard; Katrien de Jaeger; Ben J Slotman; Suresh Senan
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

8.  Ablative or palliative stereotactic body radiotherapy with helical tomotherapy for primary or metastatic lung tumor.

Authors:  Michela Marcenaro; Stefano Vagge; Liliana Belgioia; Dario Agnese; Giorgio Lamanna; Elisa Mantero; Marco Gusinu; Stefania Garelli; Francesca Cavagnetto; Stefano Agostinelli; Renzo Corvò
Journal:  Anticancer Res       Date:  2013-02       Impact factor: 2.480

Review 9.  Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.

Authors:  Sashendra Senthi; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2013-02-22       Impact factor: 6.280

10.  Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033).

Authors:  Traves Crabtree; Varun Puri; Robert Timmerman; Hiran Fernando; Jeffrey Bradley; Paul A Decker; Rebecca Paulus; Joe B Putnum; Damian E Dupuy; Bryan Meyers
Journal:  J Thorac Cardiovasc Surg       Date:  2012-11-20       Impact factor: 5.209

View more
  4 in total

1.  Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours.

Authors:  Stefano Arcangeli; Lorenzo Falcinelli; Stefano Bracci; Alessandro Greco; Alessia Monaco; Jessica Dognini; Cinzia Chiostrini; Rita Bellavita; Cynthia Aristei; Vittorio Donato
Journal:  Br J Radiol       Date:  2017-03       Impact factor: 3.039

2.  Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience.

Authors:  Vanessa Figlia; Rosario Mazzola; Francesco Cuccia; Filippo Alongi; Gianluca Mortellaro; Daniela Cespuglio; Teresa Cucchiara; Giuseppina Iacoviello; Vito Valenti; Massimo Molino; Francesco Verderame; Domenica Matranga; Antonio Lo Casto; Giuseppe Ferrera
Journal:  Radiol Med       Date:  2018-02-17       Impact factor: 3.469

Review 3.  Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients.

Authors:  L Ceniceros; J Aristu; E Castañón; C Rolfo; J Legaspi; A Olarte; G Valtueña; M Moreno; I Gil-Bazo
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

4.  Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases.

Authors:  Shuangshuang Li; Ju Yang; Juan Liu; Shanbao Gao; Baorui Liu; Jing Yan
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.